67 results
6-K
EX-99.1
MREO
Mereo Biopharma Group Plc
22 May 20
Annual General Meeting
9:31am
at home and away from others (social distancing) to address the spread of COVID-19. In accordance with these measures, it is currently expected … qualifying persons to be present at the AGM. If COVID-19 social distancing measures remain in place at the time of the AGM, any ordinary shareholder
6-K
MREO
Mereo Biopharma Group Plc
28 Apr 20
Current report (foreign)
4:10pm
by governments to stay at home or to “social distance” limits normal communications and may also increase cyber security risk or create data accessibility … uncertain and difficult to predict. In particular it is not currently known how long travel restrictions and social distancing/isolation requirements
F-4
EX-10.17
MREO
Mereo Biopharma Group Plc
25 Jan 19
Registration of securities (foreign)
12:00am
”
the meaning given by section 1159 of the Companies Act 2006;
“Tax Liability”
any tax or social security contributions liability in connection … or Shares is calculated, including whether and if so to what extent to take account of any tax or social security liability applicable to the Award
S-8
EX-99.4
MREO
Mereo Biopharma Group Plc
15 Jan 21
Registration of securities for employees
4:21pm
;
“Subsidiary”
the meaning given by section 1159 of the Companies Act 2006;
“Tax Liability”
any tax or social security contributions liability … the amount of cash or Shares is calculated, including whether and if so to what extent to take account of any tax or social security liability applicable
F-4
EX-10.16
MREO
Mereo Biopharma Group Plc
25 Jan 19
Registration of securities (foreign)
12:00am
Liability”
any tax or social security contributions liability in connection with an Award for which the Participant is liable and for which any Group … the amount of cash or Shares is calculated, including whether and if so to what extent to take account of any tax or social security liability applicable
S-8
EX-99.5
ieppus05no5 u1
15 Jan 21
Registration of securities for employees
4:21pm
6-K
EX-99.1
3ila94mfbfvupft
4 Sep 20
Current report (foreign)
7:00am
6-K
chh4p
17 Sep 19
Current report (foreign)
8:06am
6-K
EX-99.1
nuvhzs rveqt52c
27 May 20
Notice of Annual General Meeting
7:37am
F-4
EX-10.15
xdv0sau2ajamc2o
25 Jan 19
Registration of securities (foreign)
12:00am
6-K
EX-99.1
mc1c4n2wfvcozpn7yvt
2 Nov 21
Current report (foreign)
4:16pm
6-K
EX-99.1
jjeqs98pfq0b 46cuec7
6 Jul 23
Ultragenyx Announces First Patients Dosed in Phase 3 Program
8:05am
S-8
EX-99.6
ufse3er 9t
15 Jan 21
Registration of securities for employees
4:21pm
6-K
EX-99.1
3h5vfcoq
13 Jan 20
Mereo BioPharma and Oncologie Enter into Global Licensing Agreement for Navicixizumab
8:26am
6-K
EX-99.1
7pgzo
17 Sep 19
Current report (foreign)
8:06am
6-K
EX-99.2
szfo3zn
2 Nov 21
Current report (foreign)
4:16pm
6-K
EX-99.2
ztygh pu7btp2z9gc
29 Sep 20
Current report (foreign)
7:08am
425
cqmiwz cxolfgqh
6 Dec 18
Business combination disclosure
2:27pm
425
0w550r
15 Mar 19
Business combination disclosure
8:34am
6-K
EX-99.2
nqsw 386ih8
28 Oct 22
Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management
7:11am